India covid-19 patient India

Covid-19: Zydus seeks DCGI nod to undertake clinical trials for monoclonal antibodies cocktail

Reading now: 565
www.livemint.com

Covid infection.ZRC-3308 is a cocktail of 2 anti-SARS-CoV-2 monoclonal antibodies.''Zydus Cadila today announced that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19.

SARS-CoV-2 spike protein targeted, neutralizing monoclonal antibody based treatments have received emergency use authorization in mild COVID 19 in the US, Europe and in India because they significantly reduced viral load in mild patients and their rate of hospitalization,'' Cadila Healthcare said in an exchange filing.Zydus is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID-19, it said.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA